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AbstrACt
Introduction Warfarin has frequently been underused in 
older people for stroke prevention in atrial fibrillation (AF). 
Direct oral anticoagulants (DOACs) entered the UK market 
from 2008 and have been recommended as an alternative 
to warfarin. This study aimed to describe any changes in 
the prescribing of oral anticoagulants (OACs) to people 
aged ≥75 years in UK general practice before and after the 
introduction of DOACs, to examine differences in patient 
characteristics which may influence prescribers’ decisions 
regarding anticoagulation, to evaluate the time people stay 
on OACs and switching between OACs.
Methods and analysis A retrospective cohort study 
design will be used. Patients with a diagnosis of AF will 
be identified from the Clinical Practice Research Datalink 
(CPRD). The study period will run from 1 January 2003 
to 27 December 2017. Patients enter the cohort at 
the latest date of the start of the study period, first AF 
diagnosis, 75th birthday or a year from when they started 
to contribute research standard data. Follow- up continues 
until they leave the practice, death, the date the practice 
stops contributing research standard data or the end of the 
study period (27 December 2017). Exposure to OACs will 
be defined as ≥1 prescription issued for an OAC of interest 
during the study period. Patients issued an OAC in the year 
preceding study entry will be defined as ‘prevalent users’. 
Patients starting on an OAC during the study period will be 
defined as ‘incident users’. Incidence and prevalence of 
OAC prescribing, patient demographics and characteristics 
will be described during three time periods: 2003–2007, 
2008–2012 and 2013–2017. Persistence (defined as the 
time from initiation to discontinuation of medication) with 
and switching between different OACs will be described.
Ethics and dissemination The protocol for this study 
was approved by the CPRD Independent Scientific Advisory 
Committee. The results will be disseminated in a peer- 
reviewed journal and at conferences.
trial registration number EUPAS29923.
IntroduCtIon
A large body of evidence has shown that 
vitamin K antagonists (VKAs) are safe and 
effective for stroke prevention in atrial 
fibrillation (AF), but they have frequently 
been underused in older people.1 Reasons 
cited by physicians as making them less 
likely to prescribe VKAs for a person with AF 
include advancing age, risk of falls, comorbid-
ities and previous bleeding.2
The first direct oral anticoagulant (DOAC), 
dabigatran, was marketed throughout Europe 
and in the UK in 2008, but was not licensed 
for stroke prevention in AF until 2011. Since 
then, three additional DOACs have been 
licensed for prevention of stroke: rivarox-
aban, apixaban and edoxaban, and these are 
recommended in national and international 
guidelines as an alternative to warfarin.3–5 
In the UK, the National Institute of Clinical 
Excellence (NICE) produces technology 
appraisals making recommendations for new 
medicines. The National Health Service is 
strengths and limitations of this study
 ► This will be a large cohort study using a validat-
ed data source which is representative of the UK 
population.
 ► This study will explore a number of aspects of oral 
anticoagulant (OAC) prescribing and will examine 
changes over time to show any changes in OAC 
prescribing practices since the introduction of direct 
oral anticoagulants (DOACs).
 ► Analysing differences in patient demographics, co-
morbidities and coprescribing between those pre-
scribed DOACs and warfarin will provide important 
information for future studies aiming to compare 
differences in outcomes with the different OACs.
 ► This study relies on prescription data generated by 
general practices; therefore, we will not know if the 
prescribed medication was ever dispensed or taken.
 ► Warfarin dosing schedules are not recorded in the 
Clinical Practice Research Datalink, so duration of 
warfarin prescriptions will be estimated.
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legally obliged to fund those medicines recommended 
by NICE within 3 months of publication of the appraisal. 
NICE published favourable technology appraisals for 
dabigatran and rivaroxaban in 2012,6 7 apixaban in 20138 
and edoxaban in 2015,9 meaning DOACs were available 
across the UK from mid-2012 onwards for stroke preven-
tion in AF.
DOACs may allay some prescribers’ concerns when 
deciding whether to anticoagulate their older patients: 
they have fixed dosing schedules and can be added to 
compliance aids. They have also been shown in clinical 
trials to have a significantly lower risk of intracranial 
haemorrhage than warfarin10–13 (a prominent concern in 
patients with a history of falls).14
Since the introduction of DOACs, the overall rate of 
oral anticoagulant (OAC) initiation has increased by 
58%.15 However, it is not known whether the introduc-
tion of DOACs has changed the rates of OAC prescribing 
for older people (aged ≥75 years) or how patient demo-
graphics, comorbidities and concomitant prescribing 
affect the choice of anticoagulant prescribed in UK 
general practice.
This study aimed to characterise prescribing of OACs to 
people aged ≥75 years in UK general practice, before and 
after the introduction of DOACs.
objectives
1. To describe changes in the point prevalence and inci-
dence of OAC prescribing by year prior to the introduc-
tion of DOACs (2003–2007), between the introduction 
of DOACs and the time they were recommended by 
NICE for stroke prevention in AF (2008–2012), and 
following NICE recommendation (2013–2017).
2. To describe switching between OACs during the study 
period.
3. To compare the characteristics of patients with AF who 
were newly started on OACs during each period de-
scribed in objective 1 to those who were not prescribed 
anticoagulation in the same period.
4. To describe persistence with DOACs compared with 
warfarin.
MEthods And AnAlysIs
This will be a retrospective cohort study using routinely 
collected healthcare data from the Clinical Practice 
Research Datalink (CPRD) database. The CPRD contains 
anonymised medical records and prescribing data from 
general practitioners (GPs) in primary care. It contains 
data for around 7% of the UK population and is repre-
sentative in age, sex and ethnicity.16 Sociodemographic 
data, medical diagnoses, other clinical and test data are 
recorded using Read codes, and these Read codes will be 
used to identify patients to be included in the study and 
also to identify covariates as described further.
source population
The study period will start on 1 January 2003 and will end 
on 27 December 2017. The source population will consist 
of all patients in CPRD who have ≥1 Read codes for AF 
and have contributed a minimum of 12 months’ research 
standard data prior to entry into the cohort. To be eligible 
to join the study, patients need to have the following: a 
Read code for AF recorded during or any time prior to 
the start of the study period; evidence to support the diag-
nosis of AF, such as a second AF diagnosis at a later date, 
an echocardiogram or prescription for a rate limiting or 
antiarrhythmic medication in the 3 months before the AF 
diagnosis or anytime after; and age of ≥75 years at study 
entry.
Patients will enter the cohort at the latest of the 
following dates:
 ► Start of the study period.
 ► First AF diagnosis.
 ► 75th birthday.
 ► A year from the date they started to contribute 
research standard data.
Patients will be censored if they leave the practice, the 
practice stops contributing data, at their date of death 
or at the end of the study. For the incidence calculations 
and comparison of patient characteristics, patients will be 
censored when they are prescribed an OAC.
time periods
The cohort will be analysed in three time periods:
 ► Period 1: prior to the introduction of DOACs 
(2003–2007).
 ► Period 2: during the period between the introduction 
of DOACs and the time they were recommended by 
NICE (2008–2012).
 ► Period 3: following the publication of the NICE tech-
nology appraisals recommending DOACs as an option 
for stroke prevention in AF (2013–2017).
For each time period, patients will contribute data to 
either the warfarin, DOAC or no OAC group. Patients in 
the cohort can contribute data to more than one time 
period and more than one group, and may contribute 
differently for each objective. Patients may only contribute 
to the incident OAC group once with their index OAC. 
Any further prescriptions for different OACs would be 
considered to be prevalent.
Exposure
The OACs of interest in this study are warfarin, dabig-
atran, rivaroxaban, apixaban and edoxaban. Warfarin is 
the only VKA included as it is the most commonly used 
VKA in the UK. Dabigatran, rivaroxaban, apixaban and 
edoxaban are the only DOACs licensed for the preven-
tion of stroke in AF available during the study period.
All prescriptions for the OACs of interest that are issued 
following an AF diagnosis, during the study period and 
in the year prior to entry in to the study cohort will be 
identified.
 Incident and prevalent users
Exposure status will be defined at cohort entry as
by copyright.
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 ► ‘No OAC’, where the patient had at least a year free 
of OAC prior to study entry and does not receive an 
OAC during the study period.
 ► ‘Incident OAC users’, where the patient had at least 
a year free of OAC prior to study entry then was 
prescribed an OAC during the study period.
 ► ‘Prevalent OAC users’ if the patient received an OAC 
in the year prior to study entry.
Exposure status for incident OAC users will be stratified 
at the start of each study period to no OAC, warfarin or 
DOAC.
 Indication for prescribing
OACs are prescribed for many different indications, but 
only those prescribed for stroke prevention in AF will be 
included in this study. Patients will be excluded from the 
study if
 ► They had a hip fracture or hip replacement in the 
6 weeks prior to the OAC index date and only one 
prescription for an OAC.
 ► They had a venous thromboembolism in the 6 months 
prior to the OAC index date.
 DOAC prescription duration
The index date will be defined as the date the first 
prescription was issued. The expected end date will be 
calculated by dividing the number of tablets prescribed 
by the licensed number of doses per day (ie, two doses per 
day for dabigatran and apixaban and one dose per day 
for rivaroxaban and edoxaban). Where the quantity of 
tablets prescribed is not specified, the expected duration 
will be imputed from other prescriptions issued for the 
same product for that patient or overall for that product 
if patient- specific information is not available.
Patients will be classified as being continuously exposed 
until there is a gap of >60 days between the expected end 
of one prescription and the start of the next. Where there 
is a gap of ≤60 days between the expected end of one 
prescription and the start of another for the same DOAC 
(regardless of whether the strength prescribed changes), 
the gap will be filled and defined as continuous exposure. 
Where a subsequent prescription for the same product is 
issued before the expected end of the previous prescrip-
tion, the prescriptions will be concatenated and the extra 
days will be added to the expected end date of the second 
prescription. A maximum of 60 additional days will be 
allowed per patient.
A DOAC will be defined as discontinued 60 days from 
the expected end date of the last prescription issued for 
that product.
 Warfarin prescription duration
Warfarin does not have a fixed dosing schedule; the dose is 
amended based on the results of a blood test, the interna-
tional normalised ratio (INR). In the UK, patients are issued 
with different strength tablets (0.5, 1.0, 3.0 and 5.0 mg) and 
are advised, following each INR test, what dose they need to 
take and what strength of tablets to use. Dosing information 
for warfarin is not recorded in the CPRD; however, the 
strength and quantity of warfarin tablets issued by the 
general practice are recorded. Read codes for warfarin 
monitoring and results of INR tests are also recorded by 
some general practices, but this is not recorded consistently.
The index date will be defined as either the date of the 
first prescription issued or from the date of the first INR 
test result above 2 if this occurs before the first issue of a 
prescription. Patients may be exposed to warfarin before 
the first prescription issued by their GP if treatment is 
started in the hospital. CPRD data do not include hospital 
prescribing; hence, INR test results of ≥2 will be used as a 
surrogate marker of exposure.
The expected end date for warfarin prescriptions will 
be estimated using the median time between all previous 
prescriptions issued to the same patient. For example, if 
four prescriptions had been issued for 28×1 mg tablets 
and the gaps between the prescription issue dates were 
15, 35 and 42 days, we would define the final prescription 
for 28 tablets as lasting 35 days, so the expected end date 
of the last prescription would be 35 days from the issue 
date. Where multiple strengths are issued for a patient, 
the median will be calculated for each strength and the 
expected end date will be the latest of these dates.
If only one prescription has been issued, the expected 
end date will be assumed to be equal to the median 
warfarin prescription gap for the cohort.
A patient will be assumed to have discontinued warfarin 
treatment if there is a period ≥2 times their median 
prescription gap. If an INR test result of ≥2 is recorded 
in the discontinuation period (expected end date of the 
last prescription to the date equal to twice their median 
prescription gap), then INR tests will be used as a surrogate 
marker for warfarin prescribing and the end date will be 
defined as 1 week following the final INR test result of ≥2.
The procedure for warfarin mapping is illustrated in 
figure 1. This will be repeated for each strength and the 
patient classed as unexposed from the latest discontinua-
tion date of all the strengths.
 Restarting index OAC after discontinuation
There could be instances where OAC therapy is classed as 
discontinued when in fact the OAC has been continued 
but not issued by a GP if the patient is hospitalised. In 
instances where patients are classified as discontinuing 
OAC therapy but have then been ‘restarted’ on their 
index OAC, they will be reviewed individually to ascertain 
whether the OAC therapy had truly been discontinued 
or whether their records indicate another reason for the 
gap in prescribing, for example, a record indicating an 
admission to hospital.
 OAC switching
The first OAC prescribed during the study (for incident 
users) or on entry to the study (for prevalent users) will be 
defined as the index OAC. If ≥1 prescription for an alterna-
tive OAC is prescribed during the study period, the patient 
will be designated as having switched. Switches can be from
by copyright.
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Figure 1 Illustration of warfarin mapping for a single patient and one strength of warfarin tablet. Rx, prescription.
 ► Warfarin to DOAC.
 ► DOAC to warfarin.
 ► DOAC to alternative DOAC.
Patients will be assumed to have stopped the index OAC 
on the date the alternative OAC is issued if this is prior to 
the expected end date of the index OAC. Where the alter-
native OAC is prescribed after the expected end date of 
the index OAC, the time to switch will be described.
Covariate classification
It is recognised that some patients may remain in the 
cohort for a long time and their covariates may change. 
Therefore, covariates will be identified separately for each 
of the time periods the patient contributes data and will 
be grouped by DOAC, warfarin or no OAC, depending 
on exposure for that period.
We want to investigate whether certain comorbidities 
influence the prescribing of OACs. We will therefore look 
for comorbidities accumulated up to the end of the time 
period for patients who do not receive an OAC or the 
OAC index date where one is prescribed. Patients will be 
classified as having a comorbidity if the patient record 
contains ≥1 diagnostic Read code for a disease or ≥3 Read 
codes supporting the presence of the disease at any time 
prior to the relevant date for that period. Read codes used 
to support the presence of disease include attendance at 
specialist clinics (eg, diabetes clinics) or codes related to 
follow- up, such as hypertension monitoring.
Concomitant medication will be classified as≥1 prescrip-
tion issues for a medication of interest in the 3 months 
prior to study entry, commencing an OAC, or the end 
of the time period. We will describe medications at study 
entry as baseline and then in each time period for the 
no OAC and incident OAC patients as described for the 
comorbidities previously mentioned. The medications of 
interest affect either stroke or bleeding risk or commonly 
interact with OACs (antihypertensives, antiplatelets, statins, 
diabetic medications, antiarrhythmics, non- steroidal anti- 
inflammatory drugs, corticosteroids, anticonvulsants, 
systemic azoles, HIV protease inhibitors and ciclosporin).
definitions of covariates
Differences in patient demographics (age and biological 
sex) and characteristics (body mass index (BMI), smoking 
status and alcohol consumption) between those anti-
coagulated for AF and those not anticoagulated will be 
described for each period. Differences in the stroke risk 
score (Congestive heart failure, hypertension, age ≥ 75 
(doubled), diabetes mellitus, stroke (doubled), vascular 
disease, age 65-74, sex category (female) (CHA2DS2- 
VASc))17 and the bleeding risk score (Hypertension, 
abnormal renal or hepatic function, stroke, bleeding, 
labile INRs, elderly, drugs or alcohol (HAS- BLED)),18 
comorbidities and concomitant medication will also be 
described. These covariates are defined in the following 
subsections.
 CHA2DS2-VASc score
International guidelines recommend using this score to 
calculate stroke risk in patients with AF.3–5 Higher scores 
indicate an increasing risk of stroke and the maximum 
score is 9. Definitions for each element were based on 
those described by Lip and colleagues17 but have been 
modified for clarity:
 ► Congestive heart failure (1 point): right or left ventricular 
failure or heart failure. Supportive information 
includes Read codes for heart failure clinic attend-
ance or referral, heart failure monitoring or refer-
ence to heart failure therapy/education.
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 ► Hypertension (1 point): primary or secondary hyper-
tension or hypertensive disease states, for example, 
hypertensive heart disease. Supportive information 
includes codes for monitoring, referral to specialist 
clinics or reference to therapy for hypertension.
 ► Age≥75 (2 points).
 ► Diabetes mellitus (1 point): type 1 or type 2 diabetes 
mellitus diagnosis or the consequences of diabetes 
mellitus, for example, diabetic retinopathy. This also 
includes anyone prescribed oral hypoglycaemic agents 
and/or insulin, and excludes gestational diabetes and 
steroid- induced diabetes as these are often reversible. 
Supportive information includes dietary advice, refer-
ence to diabetes therapies, referral to specialist clinics 
or educational programme.
 ► Stroke/transient ischaemic attack or thromboembolism (2 
points): stroke includes ischaemic stroke transient 
ischaemic attacks and excludes haemorrhagic stroke 
and venous infarctions. Thromboembolism includes 
arterial embolic disease and surgeries to treat arterial 
emboli, and excludes thrombosis and venous embolic 
disease, which are included in vascular disease.
 ► Vascular disease (1 point): includes coronary artery 
disease (prior myocardial infarction, angina pectoris, 
percutaneous coronary intervention or coronary 
bypass surgery and aortic plaque); peripheral vascular 
disease (intermittent claudication, previous surgery 
or percutaneous intervention on the abdominal aorta, 
bifurcation or the lower extremity vessels (limited to 
surgery on the femoral, popliteal, peroneal and iliac 
arteries)); and arterial and venous thrombosis and 
excludes thromboses related to pregnancy.
 ► Age 64–74 (1 point).
 ► Female sex (score 1).
 HAS-BLED
International guidelines recommend using this score to 
assess the risk of bleeding with anticoagulants.3–5 Higher 
scores indicate an increased risk of bleeding with antico-
agulants. The presence of each disease scores one point 
and the maximum score is 9. For the purpose of this study, 
the maximum score for the HAS- BLED will be 8. The L in 
HAS- BLED corresponds to labile INR defined as a time in 
therapeutic range with warfarin of less than 60%. As INRs 
are not recorded consistently in the CPRD and because 
people prescribed DOACs would not have INR tests at all, 
this element of the score will not be included. Definitions 
for each element were based on those described by Pisters 
and colleagues18 but have been adapted to suit the infor-
mation recorded in the CPRD.
 ► Hypertension (1 point): as described for CHA2DS2- VASc 
score previously.
 ► Abnormal renal or hepatic function (1 point each, maximum 
of 2 points): renal and hepatic function will be deter-
mined using a combination of clinical Read codes and 
test results.
 – Renal impairment: includes chronic dialysis, trans-
plant and chronic renal impairment (defined as 
stage 3 or above, moderate, severe or end stage). If 
renal impairment is recorded with no severity but 
there is a test result for creatinine of ≥200 µmol/L, 
the patient will be allocated a point. If there are no 
test results recorded, the patient will score 0. Codes 
for renal disease where it does not state that renal 
function is impaired will be excluded.
 – Hepatic disease: includes chronic hepatic disease 
(cirrhosis, hepatitis, fatty liver and fibrosis), liver 
transplantation or biochemical evidence of signif-
icant hepatic derangement (bilirubin>2× upper 
limit of normal in association with aspartate ami-
notransferase/alanine aminotransferase/alkaline 
phosphatase) where these blood test results are re-
corded in CPRD.
 ► Stroke (1 point): as described for CHA2DS2- VASc score 
previously.
 ► Bleeding history or predisposition (1 point): includes any 
previous bleed; categorised based on the Interna-
tional Society of Thrombosis and Haemostasis guid-
ance as major bleeding where the bleed occurs in a 
critical area or organ or requires a blood transfusion 
(CPRD does not state the number of units infused, so 
any requirement for a blood transfusion in conjunc-
tion with a Read code for bleeding will be classified 
as a major bleed)19; or clinically relevant non- major 
bleeding (defined as a bleed not fitting the major 
bleed criteria but requiring review by a healthcare 
professional, as the codes are recorded by a GP we will 
assume that these bleeds required review)20; excludes 
codes for traumatic bleeding, bleeding related to 
pregnancy and postoperative bleeding. Predisposition 
to bleeding includes anaemia and gastric, duodenal 
and peptic ulcers.
 ► Elderly (1 point): defined as being aged >65 years old.
 ► Drugs or alcohol (1 point each, maximum of 2 points): a 
point will be allocated where a patient receives a 
prescription for an antiplatelet or non- steroidal anti- 
inflammatory medication within the time period. 
Exact alcohol consumption is not well documented 
in the CPRD, but patients will score a point for this 
element if they have any record stating the number 
of units consumed per week as >8 units or if they have 
any codes for heavy/problem drinking.
 Renal impairment
DOACs are predominantly renally cleared and so require 
dose adjustment and careful monitoring in renal impair-
ment. The elimination of warfarin is mostly metabolic, 
being metabolised by hepatic enzymes so it is not affected 
by changes in renal function. Renal impairment may 
therefore affect the decision of which anticoagulant (if 
any) to use so it has been included as a covariate alone, 
in addition to its inclusion in the HAS- BLED score. The 
Read code or test result dated closest to the relevant date 
for the period will be used to categorise the presence and 
level of renal impairment.
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pen: first published as 10.1136/bm






6 Mitchell A, et al. BMJ Open 2019;9:e032646. doi:10.1136/bmjopen-2019-032646
Open access 
Chronic renal impairment
Includes chronic dialysis, renal impairment and chronic 
kidney disease regardless of whether severity or stage 
is reported. Test results for creatinine and estimated 
glomerular filtration rate (eGFR) will also be obtained 
where available. If test results are available, they will be 
used to classify whether a patient has renal impairment 
and the stage of impairment (if eGFR is documented). 
Codes for a renal disease that may reduce kidney function 
but with no test or diagnostic code to support the pres-
ence of renal impairment will be excluded.
Acute kidney injury
Previous episodes of acute kidney injury may influence 
the decision to prescribe an anticoagulant and which 
anticoagulant to prescribe. Read codes for acute kidney 
injury will be counted as discrete events where they occur 
≥1 week apart.
 Hepatic disease
Hepatic disease is an independent risk factor for bleeding 
and also affects the metabolism of warfarin, so it may 
affect the decision to prescribe anticoagulation. Hepatic 
disease will be defined as specified under the HAS- BLED 
section.
 Previous bleed
Previous bleed includes any non- traumatic bleeding or 
haemorrhage. Bleeds will be divided in to subsections 
of major bleeding and clinically relevant non major 
bleeding (as described in HAS- BLED section), and also 
by site of bleed (intracranial bleeds, gastrointestinal 
bleeds or others).
 Dementia
Dementia include dementia (any type), Alzheimer’s 
disease and anyone prescribed an acetylcholinesterase 
inhibitor or memantine and excludes cognitive impair-
ment where there is no diagnosis of dementia.
 History of or at risk of falls
This includes any type of fall and any Read code which 
specifically indicates the practitioner is concerned that 
the patient is at risk of falling and excludes gait distur-
bances and other factors which may increase risk of falling 
but have not been defined by the GP as causing concern 
regarding falls risk.
 Fragility fractures
Fragility fractures are defined by the NICE as “…most 
commonly in the spine (vertebrae), hip (proximal femur) 
and wrist (distal radius). They may also occur in the arm 
(humerus), pelvis, ribs and other bones”.21 It is often 
not recorded in CPRD whether a fracture is thought to 
be a fragility fracture or not. Read codes for a diagnosis 
of fracture or operation to repair a fracture occurring 
in the spine, proximal femur, long bones, distal radius, 
humerus, pelvis or ribs will be included. Non- specific 
codes for osteoporotic and fragility fractures will also be 
included. Pathological fractures (unless specified that 
they are due to osteoporosis) will be excluded.
 Heart valve replacements and mitral stenosis
Historically, AF patients have been classed as having 
valvular or non- valvular AF, but definitions of these have 
varied.22 The licensing for DOACs in the UK states they 
should only be prescribed for patients with non- valvular 
AF, however, the randomised controlled trials for the 
DOACs all defined valvular AF differently and exclusion 
criteria varied.23 Recently updated European Society of 
Cardiology guidelines suggest that VKAs should be the 
preferred option for patients with mechanical heart valves 
or moderate to severe mitral stenosis.4 This co- variate 
has been included to investigate what proportion on 
DOAC and warfarin users have a history of mechanical 
heart valves or Read codes for moderate or severe mitral 
stenosis.
 Number of general practice encounters
The number of encounters with healthcare professionals 
from general practice in the year prior to study entry, the 
year preceding the OAC index date or preceding the end 
of the time period will be used as an indicator of health-
care use.
statistical analysis
Objective 1: to describe changes in the point prevalence and 
incidence of OAC prescribing by year prior to the introduction of 
DOACs (2003–2007), between the introduction of DOACs and the 
time they were recommended by NICE for stroke prevention in AF 
(2008–2012), and following NICE recommendation (2013–2017).
Only patients prescribed an OAC will contribute data to 
the incidence and prevalence calculations. For incidence, 
patients may only contribute to either the warfarin or the 
DOAC group once as they will be censored at the time 
they are prescribed an OAC. The point prevalence will 
be calculated at the midpoint of each year so will take 
account of switching. For prevalence, a patient could 
contribute to the warfarin group for some years, and the 
DOAC group for other years. Prescription mapping will 
be used to calculate the number of people with an OAC 
prescription that includes that time point as the numer-
ator and the total number of people in the cohort at that 
time point as the denominator.
The incidence of OAC prescribing will be calculated 
overall and for each specific OAC. Everyone in the cohort 
will be considered ‘at risk’ until the time they receive 
their first OAC prescription. Incidence will be calculated 
using the number of incident OAC users as the numer-
ator and person- time at risk for non- exposed persons as 
the denominator. For the person- time at risk calculation, 
the denominator will be truncated at the date of their 
first OAC prescription. Incidence will be stratified by age 
(75–84 and 85+) and sex.
Figure 2 illustrates how patients may contribute to the 
incidence and prevalence calculations throughout the 
study.
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Figure 2 Illustration showing how patients may contribute to the different groups for incidence and prevalence. The blue 
arrows show total unexposed time in the study; the red arrows indicate exposure to warfarin; the purple arrow indicates 
exposure to DOAC. The vertical arrows show the yearly incidence and prevalence calculations, and the letters in boxes 
correspond to the group the patient would contribute to for that year. Incidence and prevalence for the first D then prevalence 
only for all subsequent Ds. D, denominator; DOAC, direct oral anticoagulant; I, incidence numerator, P, prevalence numerator; X, 
left the study.
Figure 3 Illustration showing how patients contribute to 
different groups for the characteristic comparisons during 
their time in the study. The blue arrows represent individual 
patients; the stars represent the date the index OAC was 
commenced; X represents the patient leaving the study. 
The boxes describe which group the patient will contribute 
comorbidity data to for that period (OAC will be subdivided to 
warfarin or direct oral anticoagulant, depending on which was 
prescribed). OAC, oral anticoagulant.
 Objective 2: to describe switching between OACs during the study 
period
The number and percentage of patients switching 
from warfarin to DOAC, DOAC to DOAC and DOAC 
to warfarin will be calculated. The number of patients 
with multiple switches and details of the switches will be 
described. The average time to switch will be reported.
 Objective 3: to compare the characteristics of patients with AF 
who were newly started on OACs during each period described in 
objective 1, to those who were not prescribed anticoagulation in 
the same period
Demographics, characteristics, comorbidities and 
concomitant medications will be reported for the three 
time periods described. Prevalent OAC users will be 
excluded from this part of the study as we want to compare 
those started on an OAC with those who are not during 
each time period.
Patients may contribute data to more than one group, 
but they will be censored at the time they are prescribed 
their index OAC. For example, they may enter the study 
during the first time period but may not be prescribed an 
OAC until period 3. In this case, they would contribute 
data to the no- OAC group in time periods 1 and 2 
and then one of the OAC groups in period 3. If they 
entered in period 1 and started on an OAC in period 
2, they would contribute data to the no OAC group in 
period 1 and the OAC group in period 2; they would 
not contribute any data to period 3 as they would be 
censored. Figure 3 illustrates how patients contribute to 
different groups during their time in the study. Patient 
demographics (age and biological sex) and characteris-
tics (BMI, smoking status and alcohol consumption) will 
be reported as percentages in predefined categories. 
The proportion of the cohort with each of the comor-
bidities and concomitant medications will be described. 
The mean CHA2DS2- VASc and HAS- BLED scores will be 
reported.
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 Objective 4: to describe persistence with DOACs compared with 
warfarin
Duration of prescribing of DOACs will be compared with 
warfarin using Cox proportional hazards, stratified by 
DOAC and adjusted for age and other important covari-
ates identified in objective 3. All incident OAC users 
will be included. Time on OAC will be calculated as the 
difference between the discontinuation date of the OAC 
and the index date, as defined previously. Patients will 
be censored at the outcome (discontinuation of OAC 
therapy), on the date they stop contributing research 
standard data or the date of death.
All analyses will be conducted in STATA V.15.24 All 
values will be reported with 95% CIs.
 Missing data
There is likely to be a substantial amount of missing data 
for weight, BMI, smoking status and alcohol consump-
tion as these variables may not be regularly updated by 
GP practices. We will use logistic regression to ascer-
tain whether other variables (age, sex or comorbidities) 
predict whether these data are missing. If these variables 
do not predict the missing data, then we will assume 
that the data are missing at random. The proportion of 
missing data for these variables will be presented. If the 
data are missing at random, we will impute the missing 
values using multiple imputation and conduct a sensitivity 
analysis to investigate the effect of the missing data on the 
results of the analyses. However, previous studies suggest 
it may only be appropriate to impute weight and BMI.25 26
 PAtIEnt And PublIC InvolvEMEnt
Patients and the public were not involved in the produc-
tion of this protocol or in the design of the study.
dIsCussIon
A number of studies have described changes in antico-
agulation prescribing in the time since DOACs were 
introduced in the UK.15 27 28 However, none have focused 
specifically on their use in older people aged ≥75 years, 
despite older people being the largest users of anticoagu-
lants for AF. The main strength of this study is that it will 
investigate prescribing in a large cohort of older patients 
using the CPRD, which is generally representative of 
the UK population. This study will look at a number of 
different factors that may influence the prescribing of 
anticoagulants and how these have changed over time. 
The results of this study will inform future comparative 
studies between OACs as it will provide an insight to 
potential confounders which may need to be controlled 
for. A limitation of this study is defining accurately when 
patients are exposed to an anticoagulant and when 
they are not. This is particularly difficult for warfarin 
as dosing information is not included in the CPRD. A 
number of studies have compared DOACs and warfarin 
using routinely collected healthcare data, but they do not 
describe how they mapped warfarin exposure.29 30 This 
protocol is transparent in describing our planned method 
for warfarin mapping and uses both prescription and test 
result data. We will also investigate gaps in prescribing to 
establish whether patients may have been in the hospital 
or having their OAC prescribed elsewhere; this is likely 
to be more common in this age group than others and 
has been noted as a limitation in other studies.31 A 
second limitation is that comorbidities may not always be 
recorded in the CPRD, particularly where they are diag-
nosed and treated in secondary care. However, as the 
comorbidities we have chosen are chronic and likely to 
have a significant impact on patients’ health, it is likely 
that they would be recorded accurately. Finally, as it is 
difficult to predict whether prescriptions for concomitant 
medicines are still continuing at any given time, we have 
decided to assume that if a prescription was issued in the 
3 months prior to an OAC being started, the concomitant 
medicine is still continuing at that time. This is likely to 
be the case as most medications of interest are for chronic 
conditions. However, we acknowledge that it may overesti-
mate exposure to these concomitant medications.
EthICs And dIssEMInAtIon
The protocol for this study was approved by the CPRD 
Independent Scientific Advisory Committee (protocol 
18_071) and is registered with the European Network 
of Centres for Pharmacoepidemiology and Pharma-
covigilance. Results of the study will be disseminated in 
a peer- review journal with open access available within 6 
months of publication. Results will also be communicated 
at national and international conferences as appropriate.
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